← Eichor
Condition: Advanced Solid Tumor Cancer Synced from ClinicalTrials.gov · July 27, 2026

Recruiting studies: Advanced Solid Tumor Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Phase 1/Phase 2 · 10 location(s) · Eikon Therapeutics · NCT06907043An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Guangzhou FineImmune Biotechnology Co., LTD. · NCT06942143APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Phase 1 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06687070Study of ESG406 in Adults With Solid Tumors
Phase 1 · 3 location(s) · Shanghai Escugen Biotechnology Co., Ltd · NCT06979674A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 22 location(s) · Sanofi · NCT05584670A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Phase 1 · 9 location(s) · PAQ Therapeutics, Inc. · NCT07300150Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients
Phase 1/Phase 2 · 2 location(s) · Nanjing Immunophage Biotech Co., Ltd · NCT06212076A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Shanghai Shengdi Pharmaceutical Co., Ltd · NCT07231211A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06475300A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Crossignal Therapeutics, Inc. · NCT06598007EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combinatio
Phase 1/Phase 2 · 10 location(s) · Eikon Therapeutics · NCT07262619A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Phase 1 · 40 location(s) · Pfizer · NCT05355701HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT07296341SKB105 for Injection in Advanced Solid Tumors
Phase 1/Phase 2 · 2 location(s) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · NCT07380386DXP-106 in Solid Tumor Patients.
Phase 1 · 3 location(s) · Singlomics Biopharmaceuticals Zhuhai Co., Ltd. · NCT07532018Sapu003 in Advanced mTOR-sensitive Solid Tumors
Phase 1 · 1 location(s) · SAPU NANO (US) LLC · NCT07369505First In Human Study of CX-2051 in Advanced Solid Tumors
Phase 1 · 8 location(s) · CytomX Therapeutics · NCT06265688A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 · 62 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT05208762Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors
Phase 1 · 1 location(s) · Sichuan University · NCT06084286A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Phase 1 · 21 location(s) · Bristol-Myers Squibb · NCT06997029A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
Phase 1/Phase 2 · 1 location(s) · 3H Pharmaceuticals Co., Ltd. · NCT07354711HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
Phase 1/Phase 2 · 11 location(s) · Hutchmed · NCT07396584A Study of BGM-2121 in Patients With Advanced Solid Tumors
Phase 1 · 3 location(s) · BioGate Precision Medicine Corp. · NCT07346846A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors
Phase 1 · 7 location(s) · Bliss Biopharmaceutical (Hangzhou) Co., Ltd · NCT05217693A Study of ASP1002 in Adults for Treatment of Solid Tumors
Phase 1 · 15 location(s) · Astellas Pharma Global Development, Inc. · NCT05719558A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Meth
Phase N/A · 1 location(s) · Centro di Riferimento Oncologico - Aviano · NCT06028724Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Taizhou Mabtech Pharmaceutical Co.,Ltd · NCT06933069Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT05059678Study of ZGGS34 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · NCT07258121Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.